Researcher
Matthias Gijsen
- Disciplines:Biomarker discovery and evaluation, Drug discovery and development, Medicinal products, Pharmaceutics, Pharmacognosy and phytochemistry, Pharmacology, Pharmacotherapy, Toxicology and toxinology, Other pharmaceutical sciences
Affiliations
- Clinical Pharmacology and Pharmacotherapy (Division)
Member
From1 Sep 2016 → Today
Projects
1 - 4 of 4
- Optimizing Antibacterial Dosing in Special Patient PopulationsFrom24 Jan 2023 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- Antibacterial dose optimisation based on augmented renal clearance in adult critically ill patients and selected pediatric patientsFrom1 Oct 2021 → 30 Sep 2022Funding: BOF - postdoctoral mandates
- Beyond optimising drug exposure: Pharmacodynamic models to bridge the gap between exposure and response to antimicrobial treatmentsFrom15 Jul 2021 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- ANTIBACTERIAL DOSING IN SPECIAL PATIENT POPULATIONS WITH SEVERE BACTERIAL INFECTIONS: A PATIENT-ORIENTED AND COVARIATE-DRIVEN APPROACHFrom1 Oct 2016 → 30 Sep 2021Funding: BOF - Doctoral projects, BOF - doctoral mandates
Publications
1 - 10 of 29
- Predicting Beta-Lactam Target Non-Attainment in ICU Patients at Treatment Initiation: Development and External Validation of Three Novel (Machine Learning) Models(2023)
Authors: Matthias Gijsen
- Unravelling the Hepatic Elimination Mechanisms of Colistin(2023)
Authors: Matthias Gijsen, Tom De Vocht, Getahun Befirdu Abza, Nina Nauwelaerts, Pieter Annaert
Pages: 1723 - 1734 - Isavuconazole Exposure in Critically Ill Patients Treated with Extracorporeal Membrane Oxygenation: Two Case Reports and a Narrative Literature Review(2023)
Authors: Beatrijs Mertens, Omar Elkayal, Erwin Dreesen, Joost Wauters, Yves Debaveye, Pieter Vermeersch, Matthias Gijsen
- Comment on: Isavuconazole plasma concentrations in critically ill patients during extracorporeal membrane oxygenation(2022)
Authors: Beatrijs Mertens, Ruth Van Daele, Yves Debaveye, Joost Wauters, Christophe Vandenbriele, Matthias Gijsen
Pages: 3526 - 3527 - Ceftriaxone dosing based on the predicted probability of augmented renal clearance in critically ill patients with pneumonia(2022)
Authors: Erwin Dreesen, Matthias Gijsen, Omar Elkayal, Pieter Annaert, Yves Debaveye, Joost Wauters
Pages: 2479 - 2488 - Systematic Comparison of Hospital-Wide Standard and Model-Based Therapeutic Drug Monitoring of Vancomycin in Adults(2022)
Authors: Erwin Dreesen, Nada Dia, Karel Allegaert, Stefanie Desmet, Katrien Lagrou, Willy Peetermans, Yves Debaveye, Matthias Gijsen
- Meropenem Target Attainment and Population Pharmacokinetics in Critically Ill Septic Patients with Preserved or Increased Renal Function(2022)
Authors: Matthias Gijsen, Omar Elkayal, Pieter Annaert, Ruth Van Daele, Yves Debaveye, Joost Wauters, Erwin Dreesen, Isabel Spriet
Pages: 53 - 62 - The TARGET trial as a plea for model-informed precision dosing of piperacillin/tazobactam in patients with sepsis(2022)
Authors: Matthias Gijsen, Erwin Dreesen, Joost Wauters, Yves Debaveye, Isabel Spriet
Pages: 768 - 769 - Editorial for the Special Issue: "Therapeutic Drug Monitoring of Antimicrobials"(2022)
Authors: Matthias Gijsen, Karel Allegaert
- Prospective assessment of breakthrough infections and neurotoxicity and their association with cefepime trough concentrations in patients with febrile neutropenia(2022)
Authors: Matthias Gijsen, Johan Maertens, Katrien Lagrou, Stefanie Desmet, Erwin Dreesen, Willy Peetermans, Yves Debaveye, Isabel Spriet